Study #SWOGS0820
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III
MD Anderson Study Status
Not Accepting
Treatment Agent
Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine plus sulindac
Description
The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Colorectal Neoplasms
Study phase:
Phase III
Physician name:
Therese Bevers
Department:
Clinical Cancer Prevention
For general questions about clinical trials:
1-833-945-1429
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.